H.Pylori Infection Clinical Trial
Official title:
Comparison of Helicobacter Pylori Eradication Rates Between Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based Triple Therapy: A Propensity Score Matching Analysis
Gastric acid depressant play a major role in an H. pylori eradication therapy by (1) increasing the intragastric pH, which improves antibiotic stability and bioavailability; (2) increasing the intragastric pH to 6 or more, which prompts H. pylori to replicate and thus become more sensitive to antibiotics that are effective only against replicating bacteria, such as amoxicillin; (3) increasing the concentration of antibiotics in the stomach. Of antimicrobial agents against H. pylori, amoxicillin is a penicillin derivative that inhibits the synthesis of the bacterial cell wall. Therefore, amoxicillin's bactericidal effect requires the bacteria to be replicating. Amoxicillin is excreted by the kidneys, the plasma half-life is approximately 1 hour, and the bactericidal effect is time dependent. Theoretically, amoxicillin should be given 3 or 4 times daily to maximize the time above minimal inhibitory concentration (MIC) However, in most H. pylori eradication therapies, amoxicillin is given twice daily, where the estimated time above MIC attained by twice daily dosing is insufficient for amoxicillin. Because most strains of H. pylori are sensitive to amoxicillin, 3 or 4 times daily administration may be appropriate to increase the H. pylori eradication success. Nevertheless, data regarding the amoxicillin dosing interval for successful H. pylori eradication are lacking.
The investigators aim to compare the H. pylori eradication rates between twice- and four-times-daily amoxicillin administration in 2-week tegoprazan-based triple therapy. Secondary outcomes are treatment compliance and drug-related adverse event rates. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04550858 -
h.Pylori Ttt With Rebamipide
|
||
| Completed |
NCT03650543 -
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
|
Phase 4 | |
| Recruiting |
NCT04022109 -
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
|
||
| Completed |
NCT05857163 -
Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection
|
Phase 3 | |
| Not yet recruiting |
NCT06176547 -
Relation of Helicobacter Pylori in Prediabetic Patients
|
||
| Not yet recruiting |
NCT06425393 -
Intrafamilial Helicobacter Pylori Infection in Hong Kong
|
N/A | |
| Not yet recruiting |
NCT05882968 -
Prevalence of H.Pylori in CKD Patients
|
||
| Completed |
NCT03837210 -
Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen
|
Phase 2/Phase 3 | |
| Completed |
NCT02332213 -
Volatile Markers in Digestive Cancer
|
||
| Completed |
NCT03592069 -
Concomitant Versus Hybrid Regimen for H. Pylori Eradication
|
Phase 4 | |
| Completed |
NCT06315478 -
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
|
Phase 4 | |
| Not yet recruiting |
NCT05951998 -
Frequency of h.Pylori in Children With Dyspeptic Symptoms
|